ATOSSA THERAPEUTICS, INC. (ATOS)
2025-06-30 | ||||
|---|---|---|---|---|
| Income taxes benefit | - | |||
| Other expense, net | -28 | |||
| Research and development | 5,502 | |||
| General and administrative | 3,538 | |||
| Total operating expenses | 9,040 | |||
| Operating loss | -9,040 | |||
| Interest income | 645 | |||
| Loss before income taxes | -8,423 | |||
| Net loss | -8,423 | |||
| Net loss per share of common stock - basic (in dollars per share) | -0.07 | |||
| Net loss per share of common stock - diluted (in dollars per share) | -0.07 | |||
| Weighted average shares outstanding used to compute net loss per share - diluted (in shares) | 129,170,425 | |||
| Weighted average shares outstanding used to compute net loss per share- basic (in shares) | 129,170,425 | |||